Abcentra
Abcentra is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardiovascular inflammation, particularly targeting oxidized LDL to treat coronary artery disease and related conditions. Their mission is to bring new and better treatment options to patients with coronary artery disease, aiming to prevent heart attacks and improve cardiovascular health. The company focuses on developing a new class of pharmaceutical treatments that are highly differentiated from current options, leveraging knowledge of inflammation's role in heart disease.
Industries
Nr. of Employees
small (1-50)
Patents
Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
US-11690912-B2
View DetailsMethods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US-10858422-B2
View DetailsMethods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US-10434141-B2
View DetailsImmunomodulatory methods for treatment of atherosclerosis via inhibition of CD4+ T cell response to APOB100
US-8609605-B2
View Details
Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
US-11690912-B2
View DetailsMethods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US-10858422-B2
View DetailsMethods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US-10434141-B2
View DetailsImmunomodulatory methods for treatment of atherosclerosis via inhibition of CD4+ T cell response to APOB100
US-8609605-B2
View DetailsProducts
Clinical-stage anti-oxidized LDL monoclonal antibody
A clinical-stage, fully human IgG1 monoclonal antibody directed to a defined epitope on oxidized LDL / apolipoprotein B-100, developed to reduce plaque-associated inflammation and modulate vascular immune responses.
Clinical-stage anti-oxidized LDL monoclonal antibody
A clinical-stage, fully human IgG1 monoclonal antibody directed to a defined epitope on oxidized LDL / apolipoprotein B-100, developed to reduce plaque-associated inflammation and modulate vascular immune responses.
Services
Engages with diagnostic providers, academic investigators and clinical sites to run interventional studies and integrate imaging- and AI-based endpoints into study designs.
Engages with diagnostic providers, academic investigators and clinical sites to run interventional studies and integrate imaging- and AI-based endpoints into study designs.
Expertise Areas
- Clinical trial management
- Monoclonal antibody therapeutics
- Cardiovascular inflammation and atherosclerosis
- Imaging biomarker development and application
Key Technologies
- Fully human IgG1 monoclonal antibody therapeutics
- Epitope-specific antibody targeting (oxidized LDL / apoB-100)
- Computed tomography-derived perivascular fat attenuation index (FAI/PCAT)
- AI-driven cardiac CT image analysis
News & Updates
Abcentra announced the appointment of Dr. Peter Libby, MD as a Board Member. The company is advancing its therapeutic program into a phase 2b clinical trial in patients with a history of myocardial infarction and elevated coronary inflammation.
Abcentra presented results from a Phase 2a pilot trial of Orticumab, showing significant reduction in coronary inflammation in patients with psoriasis, using Caristo Diagnostics' AI technology.
Abcentra announced the appointment of Dr. Peter Libby, MD as a Board Member. The company is advancing its therapeutic program into a phase 2b clinical trial in patients with a history of myocardial infarction and elevated coronary inflammation.
Abcentra presented results from a Phase 2a pilot trial of Orticumab, showing significant reduction in coronary inflammation in patients with psoriasis, using Caristo Diagnostics' AI technology.